Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
advance NEXT: Efgartigimod IV in Primary Immune Thrombocytopenia
NCT06544499Phase 3Recruiting
- Sponsor
- argenx
- Start
- Oct 2024
- Primary completion
- Jun 2028
- Modality
- Antibody Fragments
- Countries
- 17
01
Overview
A Phase 3 trial of efgartigimod alfa in primary immune thrombocytopenia (ITP), sponsored by argenx. Started Oct 2024; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT06544499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06544499.